Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C86H134N20O19 |
Molecular Weight | 1752.1068 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 15 / 15 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@]([H])(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CC3=CC=CC=C3)[N+](C)(C)C)C(C)C)[C@@H](C)CC)([C@@H](C)O)C(=O)N[C@@H](CC4=CC=C(O)C=C4)C(=O)NCC(=O)N[C@@H](CCC([O-])=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(N)=O
InChI
InChIKey=DUQRILZXKXSRIY-RUBJUKRASA-N
InChI=1S/C86H134N20O19/c1-13-51(8)71(103-81(121)65-30-23-41-105(65)85(125)70(50(6)7)102-82(122)66(106(10,11)12)46-54-26-18-15-19-27-54)83(123)101-64(44-53-24-16-14-17-25-53)80(120)104-72(52(9)107)84(124)100-63(45-55-31-33-56(108)34-32-55)74(114)93-47-68(110)94-59(36-38-69(111)112)76(116)99-62(43-49(4)5)79(119)97-60(35-37-67(88)109)77(117)96-58(29-22-40-92-86(90)91)75(115)98-61(42-48(2)3)78(118)95-57(73(89)113)28-20-21-39-87/h14-19,24-27,31-34,48-52,57-66,70-72,107H,13,20-23,28-30,35-47,87H2,1-12H3,(H21-,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124)/t51-,52+,57-,58+,59-,60-,61-,62-,63-,64-,65-,66-,70-,71-,72-/m0/s1
Atilmotin (also known as BAX-ACC-1638), a motilin receptor agonist, is short acting, with t1/2 less than 10 min. It was shown that at doses of 6, 30 or 60 mg intravenously, it affected esophageal, lower esophageal sphincter (LES), and gastric motility. LES and gastric pressures were increased, whereas there was disruption of esophageal peristalsis characterized by lower amplitude and failed contractions. The drug can have the clinical implementation for stomach motility disorders but is needed further study.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16371080
i.v. atilmotin, 6, 30, 60 microg or vehicle (placebo) given 2 min after standardized breakfast, lunch and dinner
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C548
Created by
admin on Sat Dec 16 16:18:06 GMT 2023 , Edited by admin on Sat Dec 16 16:18:06 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C508748
Created by
admin on Sat Dec 16 16:18:06 GMT 2023 , Edited by admin on Sat Dec 16 16:18:06 GMT 2023
|
PRIMARY | |||
|
533927-56-9
Created by
admin on Sat Dec 16 16:18:06 GMT 2023 , Edited by admin on Sat Dec 16 16:18:06 GMT 2023
|
PRIMARY | |||
|
4WQQ18VL49
Created by
admin on Sat Dec 16 16:18:06 GMT 2023 , Edited by admin on Sat Dec 16 16:18:06 GMT 2023
|
PRIMARY | |||
|
C77604
Created by
admin on Sat Dec 16 16:18:06 GMT 2023 , Edited by admin on Sat Dec 16 16:18:06 GMT 2023
|
PRIMARY | |||
|
917220-41-8
Created by
admin on Sat Dec 16 16:18:06 GMT 2023 , Edited by admin on Sat Dec 16 16:18:06 GMT 2023
|
ALTERNATIVE | |||
|
300000034168
Created by
admin on Sat Dec 16 16:18:06 GMT 2023 , Edited by admin on Sat Dec 16 16:18:06 GMT 2023
|
PRIMARY | |||
|
DTXSID40201559
Created by
admin on Sat Dec 16 16:18:06 GMT 2023 , Edited by admin on Sat Dec 16 16:18:06 GMT 2023
|
PRIMARY | |||
|
73348450
Created by
admin on Sat Dec 16 16:18:06 GMT 2023 , Edited by admin on Sat Dec 16 16:18:06 GMT 2023
|
PRIMARY | |||
|
8565
Created by
admin on Sat Dec 16 16:18:06 GMT 2023 , Edited by admin on Sat Dec 16 16:18:06 GMT 2023
|
PRIMARY | |||
|
QQ-40
Created by
admin on Sat Dec 16 16:18:06 GMT 2023 , Edited by admin on Sat Dec 16 16:18:06 GMT 2023
|
PRIMARY | |||
|
CHEMBL2369989
Created by
admin on Sat Dec 16 16:18:06 GMT 2023 , Edited by admin on Sat Dec 16 16:18:06 GMT 2023
|
PRIMARY |
ACTIVE MOIETY